文献速递淋巴瘤贫血与红细胞疾病

淋巴瘤相关噬血细胞综合征高乳酸血症与单核细胞糖酵解及不良预后相关

Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis.
PubMed 文献 · Br J Haematol · 2026-07-01

该研究对初诊淋巴瘤相关噬血细胞综合征(LAHS)、非淋巴瘤相关HLH(NLAHS)及健康对照外周血行多组学分析,发现LAHS单核细胞糖酵解增强、乳酸和丙酮酸升高,高乳酸血症(>5.1 mmol/L)是LAHS不良生存的独立预测因素。

要点

  • LAHS中显著扩增的单核细胞糖酵解活性增强,尤其PTTG1+单核细胞亚群。
  • 高乳酸血症(>5.1 mmol/L)是LAHS不良生存的独立预测因素。
  • 治疗诱导缓解与高代谢表型逆转相关,提示靶向免疫代谢可能成为新策略。

核心结论

  • LAHS以显著Warburg样代谢状态为特征,主要涉及糖酵解单核细胞。
  • 高乳酸血症与LAHS不良结局相关,可能指导靶向免疫代谢通路的新治疗策略开发。

研究设计与样本

  • 对初诊LAHS、NLAHS及健康对照外周血行整合多组学分析。
  • scRNA-seq分析纳入4例LAHS、3例NLAHS、2例健康对照。
  • 代谢组学分析纳入21例LAHS、11例NLAHS、7例健康对照。
  • 临床高乳酸血症分析纳入84例,阈值>5.1 mmol/L。

主要发现

  • scRNA-seq显示LAHS单核细胞群体显著扩增且糖酵解活性增强,尤以PTTG1+单核细胞亚群为著。
  • 代谢组学证实LAHS糖酵解产物乳酸和丙酮酸水平升高。
  • 高乳酸血症(>5.1 mmol/L,n=84)是LAHS不良生存的显著独立预测因素,中位总生存仅43.5天(p<0.001)。
  • 治疗诱导缓解与高代谢表型逆转相关。
  • 细胞通讯分析显示PTTG1+单核细胞血小板反应蛋白信号上调,与糖酵解活性相关。

关键数值与推荐

  • 高乳酸血症定义为>5.1 mmol/L,在LAHS中为不良生存独立预测因素(n=84,中位OS 43.5天,p<0.001)。

临床怎么用

  • LAHS患者可监测乳酸水平,>5.1 mmol/L提示不良生存风险。
  • 治疗缓解伴随高代谢表型逆转,支持将免疫代谢通路作为潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lymphoma-associated haemophagocytic lymphohistiocytosis (HLH) represents a rare and life-threatening hyperinflammatory syndrome with a dismal prognosis, largely due to its poorly understood pathogenesis and unclear distinctions from non-lymphoma associated HLH (NLAHS). To elucidate these differences, we performed an integrated multiomics analysis on peripheral blood samples from patients with newly diagnosed lymphoma-associated HLH (LAHS), NLAHS and healthy controls (NC). Single-cell ribonucleic acid sequencing (scRNA-seq) analysis (4 LAHS, 3 NLAHS, 2 NC) revealed that LAHS is characterized by enhanced glycolytic activity in significantly expanded monocyte populations, notably within a distinct subset of pituitary tumor-transforming gene 1+ (PTTG1+) monocytes. Metabolomic profiling (21 LAHS, 11 NLAHS, 7 NC) further confirmed elevated levels of glycolytic products, such as lactate and pyruvate. Clinically, hyperlactataemia (>5.1 mmol/L, n = 84) emerged as a significant independent predictor of poor survival in LAHS, with a median overall survival of only 43.5 days (p < 0.001). Remission induced by treatment was associated with a reversal of this hypermetabolic phenotype. Cell communication analysis revealed upregulated thrombospondin signalling from PTTG1+ monocytes, linked to glycolytic activity. Our findings indicate that LAHS is characterized by a pronounced Warburg-like metabolic state, primarily involving glycolytic monocytes. Hyperlactataemia is associated with adverse outcomes and may guide the development of novel therapeutic strategies targeting immunometabolic pathways.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hu X, You L, Wang J, et al. Hyperlactataemia in lymphoma-associated haemophagocytic lymphohistiocytosis: Linked to monocytic glycolysis and adverse prognosis. Br J Haematol. 2026. PMID: 42384015. doi:10.1111/bjh.70637

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。